Argenica Therapeutics Ltd has released a press release.
Last Patient Dosed in Phase 2 Stroke Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- Updated - Main TBI Injury Study Annoucement
- ARG-007 Shows Significant Neuroprotection in Main TBI Study
- Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
- Phase 2 Stroke Clinical Trial Update
- $2.76m R&D Tax Incentive Cash Rebate Received for FY24
Later from Argenica Therapeutics
- New US Patent for Surgical Stroke
- Update on Investigational New Drug Application
- Argenica to Progress Clinical Development in TBI
- Argenica Awarded Federal Government Funding
- Argenica Receives IND Feedback From FDA
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics